From the Green & Gold Minerals Limited Prospectus (8 July 2025) and the July 2025 Equity Raising Presentation, we gain a detailed picture of a Queensland-focused gold explorer positioning itself for near-term development. The Company’s flagship Mt Wandoo project within the Chillagoe Gold Project in northern QLD anchors its gold strategy (Figure 1), while a growing rare earth element (REE) portfolio broadens its critical minerals exposure.

Western Yilgarn Limited (ASX: WYX) has released the results of a high-level geophysical interpretation over its 100%-owned Gascoyne Gold Project in Western Australia (Figure 1). Conducted by Core Geophysics Pty Ltd, the review of airborne magnetic, radiometric, and gravity data has delineated several high-priority structural and geophysical targets within the Dalgaringa Supersuite — the same host rocks as the neighbouring Glenburgh Gold Project (Benz Mining Corp, ASX: BNZ).

Cyclone Metals Limited (ASX: CLE) has announced a major step forward with the commencement of a Pre-Feasibility Study (PFS) for its 100%-owned flagship Iron Bear Project, located in the Labrador Trough, Canada (Figure 1). The appointment of global engineering firm Hatch to lead the study underscores the project’s significance and the Company’s intention to position Iron Bear as a strategic supplier of high-grade magnetite concentrate for the global steel market.

Horizon Minerals Limited (ASX: HRZ) has provided an update on the ongoing Pre-Feasibility Study (PFS) for the Black Swan Project, situated 40km northeast of Kalgoorlie-Boulder in the Western Australian Goldfields (Figure 1). The PFS incorporates mining, infrastructure, and processing studies to refurbish and repurpose the Black Swan operation into a gold processing facility.

Thunderbird Resources Limited (ASX: THB) has delivered another strong set of results from its Kookabookra Gold Project in north-eastern New South Wales (Figure 1). The latest announcement highlights continued success from surface sampling programs and the emergence of a new high-grade target, reinforcing the district-scale potential for an intrusive-related gold system.

Invion Limited (ASX: IVX) has achieved a major regulatory milestone with the United States Food and Drug Administration (FDA) granting Orphan Drug Designation (ODD) to INV043 for the treatment of anal cancer. This recognition is more than just a regulatory tick—it represents a strategic shift in the company’s development pathway

Tryptamine Therapeutics Limited (ASX: TYP) is sharpening its position in the psychedelic medicine sector with continued progress across its precision psilocin program. Focused on treating eating disorders and chronic pain, the company’s lead formulation, TRP-8803, is designed to overcome the shortcomings of oral psilocybin by delivering precision dosing, rapid onset, and a treatment model built for commercial scalability.

Lion Rock Minerals Ltd (ASX: LRM) has delivered another milestone from its Minta Rutile Project in Cameroon, with premium-grade natural rutile nuggets confirmed across multiple locations. Independent validation by TZ Minerals International (TZMI), a leading authority in the titanium sector, has reinforced the global significance of Minta, confirming that the high-purity rutile is suitable for all major end-use industries (Figure 1).

OpenLearning Limited (ASX: OLL) has taken a significant step in its Southeast Asian growth strategy with a five-year, usage-based SaaS agreement with Cebu Institute of Technology University (CIT) in the Philippines. Valued at a minimum of A$340,000 over the term, the deal will see OpenLearning’s AI-powered Learning Management System (LMS) implemented across all faculties and programs at one of the country’s most respected private universities.

Race Oncology Limited (ASX: RAC) has taken another important step forward in its mission of “protecting patients while optimising their cancer treatment.” The company has now dosed the first patient in its Phase 1 trial of RC220, the reformulated version of bisantrene designed to deliver both anti-cancer efficacy and cardioprotection.